Dr. Johann Hofmann
My Social Links

Dr. Johann Hofmann

Associate Professor
Innsbruck Medical University, Austria


Highest Degree
Ph.D. in Medical Biochemistry from Innsbruck Medical University, Austria

Share this Profile

Area of Interest:

Pharmacology and Toxicology
100%
Pharmacology
62%
Biochemistry
90%
Cancer Pharmacology
75%
Medical Toxicology
55%

Research Publications in Numbers

Books
0
Chapters
9
Articles
99
Abstracts
142

Selected Publications

  1. Toton, E., N. Lisiak, B. Rubis, J. Budzianowski, P. Gruber, J. Hofmann and M. Rybczynska, 2012. The tetramethoxyflavone zapotin selectively activates protein kinase C epsilon, leading to its Down-modulation accompanied by Bcl-2, c-Jun and c-Fos decrease. Eur. J. Pharmacol., 682: 21-28.
    CrossRef  |  PubMed  |  Direct Link  |  
  2. Paszel, A., B. Blazej Rubis, B. Barbara Bednarczyk-Cwynar, L. Lucjusz Zaprutko, M. Mariusz Kaczmarek, J. Hofmann and M. Maria Rybczynska, 2012. The oleanolic acid derivative methyl 3,11-dioxoolean-12-en-28-olate targets multidrug resistance related to ABCB1. Pharmacol. Rep., 63: 1500-1517.
    PubMed  |  Direct Link  |  
  3. Gruber, P., F. Rechfeld, J. Kirchmair, N. Hauser and M. Boehler et al., 2011. Barbituric acid derivative BAS 02104951 inhibits PKCε, PKCη, PKCε/RACK2 interaction, Elk-1 phosphorylation in HeLa and PKCΕ and η translocation in PC3 cells following TPA-induction. J. Biochem., 149: 331-336.
    CrossRef  |  PubMed  |  Direct Link  |  
  4. Florian, R., P. Gruber, J. Hofmann and J. Kirchmair, 2011. Modulators of Protein-protein interactions-novel approaches in targeting protein kinases and other pharmaceutically relevant biomolecules. Curr. Top. Med. Chem., 11: 1305-1319.
    CrossRef  |  PubMed  |  
  5. Radford, D.J., K. Wang, J.C. McNelis, A.E. Taylor and G. Hechenberger et al., 2010. Dehydroepiandrosterone sulfate directly activates protein kinase C-β to increase human neutrophil superoxide generation. Mol. Endocrinol., 24: 813-821.
    CrossRef  |  PubMed  |  Direct Link  |  
  6. Garczarczyk, D., K. Szeker, P. Galfi, A. Csordas and J. Hofmann, 2010. Protein kinase Cγ in colon cancer cells: Expression, Thr514 phosphorylation and sensitivity to butyrate-mediated upregulation as related to the degree of differentiation. Chemico-Biol. Interact., 185: 25-32.
    CrossRef  |  PubMed  |  Direct Link  |  
  7. Hofmann, J., J. Easmon, G. Purstinger, G. Heinisch and D.F. Condorelli et al., 2009. Investigations on the mechanism of action of the new antitumor compound EPH136. Invest. New Drugs, 27: 189-202.
  8. Garczarczyk, D., E. Toton, V. Biedermann, E. Rosivatz, F. Rechfeld, M. Rybczynska and J. Hofmann, 2009. Signal transduction of constitutively active protein kinase C epsilon. Cell. Signalling, 21: 745-752.
    CrossRef  |  PubMed  |  Direct Link  |  
  9. Perkhofer, S., B.E. Kehrel, M.P. Dierich, J.P. Donnelly and W. Nussbaumer et al., 2008. Human platelets attenuate Aspergillus species via Granule-dependent mechanisms. J. Infecti. Dis., 198: 1243-1246.
    CrossRef  |  PubMed  |  Direct Link  |  
  10. Hofmann, J., 2008. Resistance to chemotherapy. Br. J. Cancer, 99: 1368-1368.
    CrossRef  |  Direct Link  |  
  11. Lamy, C., J. Hofmann, H. Parrot-Lopez and P. Goekjian, 2007. Synthesis of a fluoroalkene peptidomimetic precursor of N-acetyl-l-glutamyl-l-alanine. Tetrahedron Lett., 48: 6177-6180.
    CrossRef  |  Direct Link  |  
  12. Ol'shevskaya, V.A., A.V. Zaitsev, V.N. Luzgina, T.T. Kondratieva and O.G. Ivanov et al., 2006. Novel boronated derivatives of 5,10,15,20-tetraphenylporphyrin: Synthesis and toxicity for drug-resistant tumor cells. Bioorganic Med. Chem., 14: 109-120.
    CrossRef  |  PubMed  |  Direct Link  |  
  13. Garczarczyk, D., F. Rechfeld, G. Hechenberger and J. Hofmann, 2006. Protein kinase C isozymes-targets for potential therapies. DOSIS, 22: 93-103.
  14. Easmon, J., G. Purstinger, K.S. Thies, G. Heinisch and J. Hofmann, 2006. Synthesis, structure-activity relationships, and antitumor studies of 2-benzoxazolyl hydrazones derived from alpha-(N)-acyl heteroaromatics. J. Med. Chem., 49: 6343-6350.
    CrossRef  |  PubMed  |  Direct Link  |  
  15. Shishkin, A.A., O.G. Ivanov, A.V. Zaitsev, E.G. Kononova and E.A. Malinina et al., 2005. The Copper-containing monocarboranylporphyrin: A prototype of new DNA-binding cytotoxic compounds. Doklady Biochem. Biophys., 403: 313-316.
    CrossRef  |  PubMed  |  Direct Link  |  
  16. Margesin, R., H. Dieplinger, J. Hofmann, B. Sarg and H. Lindner, 2005. A Cold-active extracellular metalloprotease from Pedobacter cryoconitis-production and properties. Res. Microbiol., 156: 499-505.
    CrossRef  |  PubMed  |  Direct Link  |  
  17. Hofmann, J., 2004. Protein kinase C isozymes as potential targets for anticancer therapy. Current Cancer Drug Targets, 4: 125-146.
    CrossRef  |  PubMed  |  
  18. Rybczynska, M., R. Liu, P. Lu, F.J. Sharom and E. Steinfels et al., 2001. MDR1 causes resistance to the antitumour drug miltefosine. Br. J. Cancer, 84: 1405-1411.
    CrossRef  |  PubMed  |  Direct Link  |  
  19. Rybczynska, M., M. Spitaler, N.G. Knebel, G. Boeck, H. Grunicke and J. Hofmann, 2001. Effects of miltefosine on various biochemical parameters in a panel of tumor cell lines with different sensitivities. Biochem. Pharmacol., 62: 765-772.
    CrossRef  |  PubMed  |  Direct Link  |  
  20. Mwanjewe, J., M. Spitaler, M. Ebner, M. Windegger and M. Geiger et al., 2001. Regulation of phospholipase D isoenzymes by transforming Ras and atypical protein kinase C-i. Biochem. J., 359: 211-217.
    Direct Link  |  
  21. Hofmann, J., 2001. Protein kinase C und die modulation der multidrug resistenz. Symp. Med. Oncol., 12: 12-13.
  22. Hofmann, J., 2001. Modulation of Protein Kinase C in Antitumor Treatment. In: Reviews of Physiology, Biochemistry and Pharmacology, Hofmann, J. (Ed.). Springer, Berlin Heidelberg, pp: 1-96.
    CrossRef  |  PubMed  |  Direct Link  |  
  23. Easmon, J., G. Purstinger, G. Heinisch, T. Roth and H.H. Fiebig et al., 2001. Synthesis, cytotoxicity, and antitumor activity of copper(II) and iron(II) complexes of 4N-azabicyclo[3.2.2]nonane thiosemicarbazones derived from acyl diazines. J. Med. Chem., 44: 2164-2171.
    CrossRef  |  PubMed  |  Direct Link  |  
  24. Easmon, J., G. Puerstinger, T. Roth, H.H. Fiebig and M. Jenny et al., 2001. 2-benzoxazolyl and 2-benzimidazolyl hydrazones derived from 2-acetylpyridine: A novel class of antitumor agents. Int. J. Cancer, 94: 89-96.
    CrossRef  |  PubMed  |  Direct Link  |  
  25. Conseil, G., J.M. Perez-Victoria, J.M. Jault, F. Gamarro, A. Goffeau, J. Hofmann and A. di Pietro, 2001. Protein kinase C effectors bind to multidrug ABC transporters and inhibit their activity. Biochemistry, 40: 2564-2571.
    CrossRef  |  PubMed  |  Direct Link  |  
  26. Spitaler, M., B. Wiesenhofer, V. Biedermann, T. Seppi, J. Zimmermann, H. Grunicke and J. Hofmann, 1999. The involvement of protein kinase C isoenzymes alpha, epsilon and zeta in the sensitivity to antitumor treatment and apoptosis induction. Anticancer Res., 19: 3969-3976.
    PubMed  |  
  27. Utz, I., M. Spitaler, M. Rybczynska, C. Ludescher, W. Hilbe, U. Regenass, H. Grunicke and J. Hofmann, 1998. Reversal of multidrug resistance by the staurosporine derivatives CGP 41251 and CGP 42700. Int. J. Cancer, 77: 64-69.
    PubMed  |  Direct Link  |  
  28. Spitaler, M., I. Utz, W. Hilbe, J. Hofmann and H.H. Grunicke, 1998. PKC-independent modulation of Multidrug resistance in cells with mutant (V185) but not wild-type (G185) P-glycoprotein by bryostatin 1. Biochem. Pharmacol., 56: 861-869.
    CrossRef  |  PubMed  |  Direct Link  |  
  29. Pall, G., M. Spitaler, J. Hofmann, J. Thaler and C. Ludescher, 1997. Multidrug resistance in acute leukemia: A comparison of different diagnostic methods: Phenotypic and genotypic analyses of multidrug resistance (MDR) in clinical hospital practice. Leukemia, 11: 1067-1072.
  30. Hofmann, J., I. Utz, M. Spitaler, S. Hofer and M. Rybczynska et al., 1997. Resistance to the new Anti-cancer phospholipid ilmofosine (BM 41 440). Br. J. Cancer, 76: 862-869.
    CrossRef  |  PubMed  |  Direct Link  |  
  31. Hofmann, J., 1997. The potential for Isoenzyme-selective modulation of protein kinase C. FASEB J., 11: 649-669.
    PubMed  |  Direct Link  |  
  32. Easmon, J., G. Heinisch, J. Hofmann, T. Langer, H.H. Grunicke, J. Fink and G. Pirstinger, 1997. Thiazoyl and benzothiazoyl hydrazones derived from-(N)-acetylpyridines and diazines: Synthesis, antiproliferative activity and CoMFA studies. Eur. J. Med. Chem., 32: 397-408.
  33. Easmon, J., G. Heinisch, G. Purstinger, T. Langer, J.K. Osterreicher, H.H. Grunicke and J. Hofmann, 1997. Azinyl and diazinyl hydrazones derived from aryl N-heteroaryl ketones: Synthesis and antiproliferative activity. J. Med. Chem., 40: 4420-4425.
    CrossRef  |  PubMed  |  Direct Link  |  
  34. Gekeler, V., R. Boer, F. Uberall, W. Ise and C. Schubert et al., 1996. Effects of the selective bisindolylmaleimide protein kinase C inhibitor GF 109203X on P-glycoprotein-mediated multidrug resistance. Br. J. Cancer, 74: 897-905.
    PubMed  |  
  35. Utz, I., V. Gekeler, W. Ise, J. Beck, M. Spitaler, H. Grunicke and J. Hofmann, 1995. Protein kinase C isoenzymes, p53, accumulation of rhodamine 123, glutathione-S-transferase, topoisomerase II and MRP in multidrug resistant cell lines. Anticancer Res., 16: 289-296.
    PubMed  |  Direct Link  |  
  36. Ludescher, C., W. Eisterer, W. Hilbe, M. Gotwald and J. Hofmann et al., 1995. Low frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic leukemia compared to acute myeloid leukemia. Leukemia, 9: 350-356.
    PubMed  |  
  37. Ludescher, C., W. Eisterer, W. Hilbe, J. Hofmann and J. Thaler, 1995. Decreased potency of MDR-modulators under serum conditions determined by a functional assay. Br. J. Haematol., 91: 652-657.
    CrossRef  |  PubMed  |  Direct Link  |  
  38. Hofmann, J., V. Gekeler, W. Ise, A. Noller and J. Mitterdorfer et al., 1995. Mechanism of action of dexniguldipine-HCl (B8509-035), a new potent modulator of multidrug resistance. Biochem. Pharmacol., 49: 603-609.
    CrossRef  |  PubMed  |  Direct Link  |  
  39. Hofmann, J. and C. Ludescher, 1995. Multiple resistenz gegen zytostatika. Berichte OGKC, 18: 153-157.
  40. Utz, I., S. Hofer, U. Regenass, W. Hilbe, J. Thaler, H. Grunicke and J. Hofmann, 1994. The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance. Int. J. Cancer, 57: 104-110.
    CrossRef  |  PubMed  |  Direct Link  |  
  41. Ludescher, C., W. Hilbe, W. Eisterer, E. Preuβ, J. Hofmann and J. Thaler, 1994. Funktionelle erfassung P-glykoprotein-exprimierender zellen mittels durchflusszytometrie. Wiener Klin. Wochenschr., 106: 242-246.
  42. Hofmann, J., P.M. Oconnor, J. Jackman, C. Schubert, F. Ueberall, K.W. Kohn and H. Grunicke, 1994. The protein kinase C inhibitor ilmofosine (BM 41 440) arrests cells in G2 phase and suppresses CDC2 kinase activation through a mechanism different from that of DNA damaging agents. Biochem. Biophys. Res. Commun., 199: 937-943.
    CrossRef  |  PubMed  |  Direct Link  |  
  43. Grunicke, H., J. Hofmann and I. Utz, 1994. Role of protein kinases in antitumor drug resistance. Ann. Hematol., 69: S1-S6.
    CrossRef  |  PubMed  |  Direct Link  |  
  44. Ludescher, C., W. Hilbe, W. Eisterer, J. Thaler, M. Gotwald and J. Hofmann, 1993. Low incidence of activity of P-glycoprotein (P-170) in de novo acute lymphoblastic leukemia determined by a flow cytometric assay. Blood, 82: 3505-3507.
    PubMed  |  Direct Link  |  
  45. Ludescher, C., W. Hilbe, W. Eisterer, E. Preuβ and C. Huber et al., 1993. Activity of P-glycoprotein in B-cell chronic lymphocytic leukemia determined by a flow cytometric assay. J. Natl. Cancer Inst., 85: 1751-1758.
    CrossRef  |  PubMed  |  Direct Link  |  
  46. Ludescher, C., J. Thaler, D. Drach, J. Drach and M. Spitaler et al., 1992. Detection of activity of P-glycoprotein in human tumour samples using rhodamine 123. Br. J. Haematol., 82: 161-168.
    CrossRef  |  PubMed  |  Direct Link  |  
  47. Hofmann, J., A. Wolf, M. Spitaler, G. Bock, J. Drach, C. Ludescher and H. Grunicke, 1992. Reversal of multidrug resistance by B859-35, a metabolite of B859-35, niguldipine, verapamil and nitrendipine. J. Cancer Res. Clin. Oncol., 118: 361-366.
    CrossRef  |  PubMed  |  Direct Link  |  
  48. Grunicke, H. and J. Hofmann, 1992. Cytotoxic and cytostatic effects of antitumor agents induced at the plasma membrane level. Pharmacol. Ther., 55: 1-30.
    CrossRef  |  PubMed  |  Direct Link  |  
  49. Uberall, F., K. Maly, A. Egle, W. Doppler, J. Hofmann and H.H. Grunicke, 1991. Inhibition of cell proliferation, protein kinase C and phorbol Ester-induced fos expression by the dihydropyridine derivative B859-35. Cancer Res., 51: 5821-5825.
    PubMed  |  Direct Link  |  
  50. Ludescher, C., J. Drach, J. Hofmann and H. Grunicke, 1991. Rapid functional assay for the detection of multidrug-resistant cells using the fluorescent dye rhodamine 123 [letter; comment]. Blood, 78: 1385-1387.
    PubMed  |  Direct Link  |  
  51. Hofmann, J., F. Ueberall, A.E. And and H. Grunicke, 1991. B-859-35, a new drug with anti-tumor activity reverses Multi-drug resistance. Int. J. Cancer, 47: 870-874.
    CrossRef  |  PubMed  |  Direct Link  |  
  52. Hofmann, J., H.H. Fiebig, B.R. Winterhalter, D.P. Berger and H. Grunicke, 1990. Enhancement of the antiproliferative activity of Cis-diamminedichloroplatinum(II) by quercetin. Int. J. Cancer, 45: 536-539.
    CrossRef  |  PubMed  |  Direct Link  |  
  53. Hofmann, J., F. Uberall, L. Posch, K. Maly, D.B.J. Herrmann and H. Grunicke, 1989. Synergistic enhancement of the Anti-proliferative activity of Cis-diamminedichloro-platinum(II) by the new ether lipid analogue BM 41 440, an inhibitor of protein kinase C. Lipids, 24: 312-317.
  54. Grunicke, H., J. Hofmann, K. Maly, F. Uberall, L. Posch, H. Oberhuber and H. Fiebig, 1989. The phospholipid- and Calcium-dependent protein kinase as a target in tumor chemotherapy. Adv. Enzyme Regulat., 28: 201-216.
    CrossRef  |  PubMed  |  Direct Link  |  
  55. Maly, K., W. Doppler, H. Oberhuber, H. Meusburger, J. Hofmann, R. Jaggi and H.H. Grunicke, 1988. Desensitization of the Ca2+-mobilizing system to serum growth factors by Ha-ras and v-mos. Mol. Cell. Biol., 8: 4212-4216.
    PubMed  |  Direct Link  |  
  56. Hofmann, J., W. Doppler, A. Jakob, K. Maly, L. Posch, F. Uberall and H.H. Grunicke, 1988. Enhancement of the antiproliferative effect of cis-diamminedichloroplatinum(II) and nitrogen mustard by inhibitors of protein kinase C. Int. J. Cancer, 42: 382-388.
    CrossRef  |  PubMed  |  Direct Link  |  
  57. Helliger, W., J. Hofmann, K. Maly, W. Doppler and B.J. Hermann et al., 1988. Differential sensitivity of histone acetylation in nitrogen-mustard sensitive and resistant cells. Relation to drug uptake, formation and repair of DNA-interstrand cross-links. Eur. J. Cancer Clin. Oncol., 24: 1861-1868.
    CrossRef  |  PubMed  |  Direct Link  |  
  58. Doppler, W., J. Hofmann, K. Maly and H.H. Grunicke, 1988. Protection of Ehrlich ascites tumor cells against the antiproliferative effect of mechlorethamine (nitrogen mustard) by 5-N,N-dimethylamiloride. Cancer Res., 48: 2454-2457.
    PubMed  |  Direct Link  |  
  59. Doppler, W., J. Hofmann, K. Maly and H. Grunicke, 1987. Amiloride and 5-N, N-dimethylamiloride inhibit the carrier mediated uptake of choline in Ehrlich ascites tumor cells. Biochem. Pharmacol., 36: 1645-1649.
    CrossRef  |  PubMed  |  Direct Link  |  
  60. Grunicke, H., W. Helliger, B.J. Hermann, W. Hock, J. Hofmann and B. Puschendorf, 1986. Alkylating antitumor agents reduce histone Acetyl-transferase activity. Adv. Enzyme Regulat., 25: 87-90.
    CrossRef  |  PubMed  |  Direct Link  |  
  61. Grunicke, H., W. Doppler, W. Helliger, B.J. Hermann, J. Hofmann, H. Lindner and B. Puschendorf, 1986. Progress in tumorchemotherapy based on advances in tumorbiochemistry. Arch. Geschwulstforsch, 56: 183-191.
  62. Grunicke, H., W. Doppler, S.A.E. Finch, R. Greinert and K. Grunewald et al., 1985. Effects of nitrogen mustard on potassium transport systems and membrane structure of ehrlich ascites tumor cells. Adv. Enzyme Regulat., 23: 277-290.
    CrossRef  |  PubMed  |  Direct Link  |  
  63. Grunicke, H., W. Doppler, J. Hofmann, H. Lindner and K. Maly et al., 1985. Plasma membrane as target of alkylating agents. Adv. Enzyme Regulat., 24: 247-261.
    CrossRef  |  PubMed  |  Direct Link  |  
  64. Doppler, W., J. Hofmann, H. Oberhuber, K. Maly and H. Grunicke, 1985. Nitrogen mustard interference with potassium transport systems in Ehrlich ascites tumor cells. J. Cancer Res. Clin. Oncol., 110: 35-41.
    CrossRef  |  PubMed  |  Direct Link  |  
  65. Klocker, H., B. Auer, H.J. Burtscher, J. Hofmann, M. Hirsch-Kauffmann and M. Schweiger, 1982. A sensitive radioimmuno assay for thymine dimers. Mol. General Genet., 186: 475-477.
    CrossRef  |  PubMed  |  Direct Link  |  
  66. Hofmann, J. and A. Pfitscher, 1982. Correlations of enzyme-activities in soil. Z. Pflanzenernaehr. Bodenk., 145: 36-41.
  67. Hofmann, J. and A. Pfitscher, 1982. Changing of microbial activities in alpine soils under ski slopes and foot pathes. Pedobiologia, 23: 105-111.